Cargando…
Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy
INTRODUCTION: Clinical evidence for patients with synchronous brain oligometastatic non-small-cell lung carcinoma is limited. We aimed to summarize the clinical data of these patients to explore the survival prognostic factors for this population. METHODS: From September 1995 to July 2011, patients...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948689/ https://www.ncbi.nlm.nih.gov/pubmed/27471395 http://dx.doi.org/10.2147/OTT.S106696 |
_version_ | 1782443313290280960 |
---|---|
author | Bai, Hao Xu, Jianlin Yang, Haitang Jin, Bo Lou, Yuqing Wu, Dan Han, Baohui |
author_facet | Bai, Hao Xu, Jianlin Yang, Haitang Jin, Bo Lou, Yuqing Wu, Dan Han, Baohui |
author_sort | Bai, Hao |
collection | PubMed |
description | INTRODUCTION: Clinical evidence for patients with synchronous brain oligometastatic non-small-cell lung carcinoma is limited. We aimed to summarize the clinical data of these patients to explore the survival prognostic factors for this population. METHODS: From September 1995 to July 2011, patients with 1–3 synchronous brain oligometastases, who were treated with stereotactic radiosurgery (SRS) or surgical resection as the primary treatment, were identified at Shanghai Chest Hospital. RESULTS: A total of 76 patients (22 patients underwent brain surgery as primary treatment and 54 patients received SRS) were available for survival analysis. The overall survival (OS) for patients treated with SRS and brain surgery as the primary treatment were 12.6 months (95% confidence interval [CI] 10.3–14.9) and 16.4 months (95% CI 8.8–24.1), respectively (adjusted hazard ratio =0.59, 95% CI 0.33–1.07, P=0.08). Among 76 patients treated with SRS or brain surgery, 21 patients who underwent primary tumor resection did not experience a significantly improved OS (16.4 months, 95% CI 9.6–23.2), compared with those who did not undergo resection (11.9 months, 95% CI 9.7–14.0; adjusted hazard ratio =0.81, 95% CI 0.46–1.44, P=0.46). Factors associated with survival benefits included stage I–II of primary lung tumor and solitary brain metastasis. CONCLUSION: There was no significant difference in OS for patients with synchronous brain oligometastasis receiving SRS or surgical resection. Among this population, the number of brain metastases and stage of primary lung disease were the factors associated with a survival benefit. |
format | Online Article Text |
id | pubmed-4948689 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49486892016-07-28 Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy Bai, Hao Xu, Jianlin Yang, Haitang Jin, Bo Lou, Yuqing Wu, Dan Han, Baohui Onco Targets Ther Original Research INTRODUCTION: Clinical evidence for patients with synchronous brain oligometastatic non-small-cell lung carcinoma is limited. We aimed to summarize the clinical data of these patients to explore the survival prognostic factors for this population. METHODS: From September 1995 to July 2011, patients with 1–3 synchronous brain oligometastases, who were treated with stereotactic radiosurgery (SRS) or surgical resection as the primary treatment, were identified at Shanghai Chest Hospital. RESULTS: A total of 76 patients (22 patients underwent brain surgery as primary treatment and 54 patients received SRS) were available for survival analysis. The overall survival (OS) for patients treated with SRS and brain surgery as the primary treatment were 12.6 months (95% confidence interval [CI] 10.3–14.9) and 16.4 months (95% CI 8.8–24.1), respectively (adjusted hazard ratio =0.59, 95% CI 0.33–1.07, P=0.08). Among 76 patients treated with SRS or brain surgery, 21 patients who underwent primary tumor resection did not experience a significantly improved OS (16.4 months, 95% CI 9.6–23.2), compared with those who did not undergo resection (11.9 months, 95% CI 9.7–14.0; adjusted hazard ratio =0.81, 95% CI 0.46–1.44, P=0.46). Factors associated with survival benefits included stage I–II of primary lung tumor and solitary brain metastasis. CONCLUSION: There was no significant difference in OS for patients with synchronous brain oligometastasis receiving SRS or surgical resection. Among this population, the number of brain metastases and stage of primary lung disease were the factors associated with a survival benefit. Dove Medical Press 2016-07-11 /pmc/articles/PMC4948689/ /pubmed/27471395 http://dx.doi.org/10.2147/OTT.S106696 Text en © 2016 Bai et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Bai, Hao Xu, Jianlin Yang, Haitang Jin, Bo Lou, Yuqing Wu, Dan Han, Baohui Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy |
title | Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy |
title_full | Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy |
title_fullStr | Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy |
title_full_unstemmed | Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy |
title_short | Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy |
title_sort | survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948689/ https://www.ncbi.nlm.nih.gov/pubmed/27471395 http://dx.doi.org/10.2147/OTT.S106696 |
work_keys_str_mv | AT baihao survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy AT xujianlin survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy AT yanghaitang survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy AT jinbo survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy AT louyuqing survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy AT wudan survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy AT hanbaohui survivalprognosticfactorsforpatientswithsynchronousbrainoligometastaticnonsmallcelllungcarcinomareceivinglocaltherapy |